Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

NCT07244393 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions

DRUG: Lutetium (177Lu) DGUL
DRUG: Pembrolizumab

Sponsor

Cellbion Co., Ltd.

Collaborators

[object Object]